Table 2.
Japanese encephalitis vaccines licensed for use in Korea
Type of vaccine | Manufacturer | Trade name | Virus strain | Substrate | Immunization schedule |
---|---|---|---|---|---|
JE-MBa) | Greencross | Greencross Japanese encephalitis vaccine | Nakayama | Mouse brain | Days 0, 7–30 at 12–23 months of age; booster after 1 year, then 6, 12 years of age |
Boryung Biopharma | Boryung Japanese encephalitis vaccine | ||||
Boryung Japanese encephalitis vaccine PFS | |||||
JE-VC | Boryung Biopharma | Boryung cell-culture Japanese encephalitis vaccine | Beijing-1 | Vero cells | |
Greencross cell-culture Japanese encephalitis vaccine | |||||
LJEV | Glovax | CD.JEVAX | SA-14-14-2 | PHK cells | 1st dose at 12–23 months of age; 2nd dose 12 months after 1st dose |
JE-CV | Sanofi Pasteur | IMOJEV | SA14-14-2/yellow fever 17D | Vero cells |
JE-CV, recombinant chimeric virus vaccine; JE-MB, inactivated Japanese encephalitis vaccine; JE-VC, inactivated Vero cell-derived Japanese encephalitis vaccine; LJEV, live-attenuated Japanese encephalitis vaccine; PHK, primary hamster kidney.
JE-MB is not currently in use and has been replaced by JE-VC.
Adapted from the Korean Pediatric Society. Japanese encephalitis vaccines. In: Kim JH, editor. Immunization guideline. 9th ed. [16]